ReviewInternational journal of molecular sciences2022
The Neuroprotective Potentiality of Flavonoids on Alzheimer's Disease.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Enzyme Inhibition by Bioactive Compounds from Olive (Molecules (Basel, Switzerland) · 2026Pooled it
- Genistein - A Broad-spectrum Bioactive Compound with Diverse Pharmacological Potential: A Systematic Review.Current molecular medicine · 2026Pooled it
- Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives.Redox report : communications in free radical research · 2026Review
- Plant-derived phytochemicals for Alzheimer's disease: mechanisms of action, experimental evidence, and therapeutic perspectives.Journal of natural medicines · 2026Review
- Oxyberberine-nanoparticle attenuates the cognitive deficits in a transgenic mouse model of Alzheimer's disease via modulating gut microbiota through suppressing CXCL10/CXCR3 pathway.Acta pharmacologica Sinica · 2026Article
- Quercetin Activates NRF2/SLC7A11/GPX4 Signaling to Restore Mitochondrial Function Inhibit Ferroptosis Thereby Alleviating Doxorubicin-Induced Cardiotoxicity.Biomolecules · 2026Article
- Study on the structure-activity relationships of natural γ-pyranone products and their derivatives with anti-AD activities focusing on metal chelation.Molecular diversity · 2026Review
- Targeting Neurodegeneration With Naringenin: Mechanistic Perspectives and Therapeutic Implications.Molecular nutrition & food research · 2026Review
- Integrative Metabolomic Evidence of Bioactive Food-Derived Compounds Targeting Alzheimer's Disease: A Cross-Study Analysis inInternational journal of molecular sciences · 2026Article
- Phytochemicals in Alzheimer's Disease Prevention and Management: Molecular Mechanisms, Therapeutic Potential, Translational Challenges, and Emerging Research Directions.International journal of molecular sciences · 2026Review
- Targeted Metabolomics Combined with OPLS-DA to Analyze the Differences in Phenolic Compounds in Wampee.Foods (Basel, Switzerland) · 2026Article
- Rhamnazin attenuates Amyloid β-Peptide (1-42) induced spatial memory impairments by modulation of BDNF-ERK signaling pathway.3 Biotech · 2026Article
- The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross-Sectional Study.Chemical biology & drug design · 2026Article
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Network Pharmacology Reveals the Therapeutic Potential of BBB-Permeable Compounds fromInternational journal of molecular sciences · 2026Article
- Integrative In Silico and In Vivo Evidence of Quercetin as a Multitarget Neuroprotective Agent in Alzheimer's Disease.ACS omega · 2026Article
- Molecular Structural Features and Tandem Mass Spectral Characteristics of Flavonoids From the Analysis of the LIPID MAPS Database.Chemistry & biodiversity · 2026Review
- Protective Effects of Pomiferin on Aluminum Chloride-induced Memory Impairment: Evidence from Behavioral, Biochemical, and Insilico Studies.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Neuroprotective Effects of Time-Restricted Feeding Combined With Different Protein Sources in MPTP-Induced Parkinson's Disease Mice Model and Its Modulatory Impact on Gut Microbiota Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Valorization of Sea Buckthorn, Black Chokeberry, and Black Currant Branch Biomass as a Novel Source of Bioactive Oligomeric Proanthocyanidins.Plants (Basel, Switzerland) · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), due to its spread, has become a global health priority, and is characterized by senile dementia and progressive disability. The main cause of AD and other neurodegenerations (Huntington, Parkinson, Amyotrophic Lateral Sclerosis) are aggregated protein accumulation and oxidative damage. Recent research on secondary metabolites of plants such as polyphenols demonstrated that they may slow the progression of AD. The flavonoids' mechanism of action in AD involved the inhibition of acetylcholinesterase, butyrylcholinesterase, Tau protein aggregation, β-secretase, oxidative stress, inflammation, and apoptosis through modulation of signaling pathways which are implicated in cognitive and neuroprotective functions, such as ERK, PI3-kinase/Akt, NFKB, MAPKs, and endogenous antioxidant enzymatic systems. This review focuses on flavonoids and their role in AD, in terms of therapeutic potentiality for human health, antioxidant potential, and specific AD molecular targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.